BAFF inhibition: a new class of drugs for the treatment of autoimmunity |
| |
Authors: | Liu Zheng Davidson Anne |
| |
Affiliation: | aCenter for Autoimmune and Musculoskeletal Diseases, Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY 11030, USA |
| |
Abstract: | BAFF (BLyS) and APRIL are TNF-like cytokines that support survival and differentiation of B cells. Recent studies have discovered a role for BAFF in augmenting both innate and adaptive immune responses as well as in collaborating with other inflammatory cytokines to promote the activation and differentiation of effector immune cells. BAFF is an important pathogenic factor in lupus mouse models and BAFF inhibition successfully delays disease onset in these mice, although the responsiveness to BAFF inhibition varies among different strains. These results have led to the development of inhibitors targeting BAFF and APRIL in humans. An anti-BAFF antibody has shown significant but modest efficacy in two Phase III clinical trials for moderately active SLE and other inhibitors are being developed or at early stages of clinical testing. |
| |
Keywords: | Abbreviations: SLE, systemic lupus erythematosus APRIL, a proliferation inducing ligand BAFF, B cell activating factor belonging to the TNF family (also known as BLyS B lymphocyte stimulator) TACI, transmembrane activator and calcium modulator ligand interactor BCMA, B cell maturation antigen BAFF-R, BAFF receptor HSPG, heparan sulfate proteoglycan TLR, toll like receptor IFN, interferon BCR, B-cell receptor RA, rheumatoid arthritis MS, multiple sclerosis |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|